La cadena de opciones muestra datos clave de las opciones de acciones de Viracta Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Viracta Therapeutics..

Viracta Therapeutics (OTC:VIRX) Bolsa, Cadena de Opciones

Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

EVAX

IDAI

INTZ

LIDR

LKCO

LUXH

MGIH

MLGO

MRBK

MTRX

NEUP

ONDS

QRHC

RVSN

SLDP

VIRX

WTBA

Descubre las acciones que lideran los movimientos en la apertura del mercado, incluyendo repuntes destacados y caídas sorprendentes.

Acciones de Evaxion Biotech (EVAX) suben alrededor del 62%; 20 acciones que se mueven en el premercado

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

CSTM

GDYN

GEAR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: CSTM, VIRX, EVAX, AREN y GDYN.

5 acciones en el foco este viernes: CSTM, VIRX, EVAX, AREN y GDYN

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

Village Super Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLGEA#NASDAQ">VLGEA</a>) reported quarterly earnings of $1.14 per share. This is a 17.53 percent increase over earnings of $0.97 per share from the same period last year. The company reported $599.65 million in sales this quarter. This is a 4.18 percent increase over sales of $575.58 million the same period last year.

Earnings

VLGEA

Village Super Market Q2 EPS $1.14 Up From $0.97 YoY, Sales $599.65M Up From $575.58M YoY

WIIM

NYAX

Nayax shares are trading lower after the company reported worse-than-expected Q4 financial results.

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">43.60</td>
<td align="right">0.08</td>
<td align="right">0.18</td>
<td>5.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">83.63</td>
<td align="right">0.11</td>
<td align="right">0.13</td>
<td>13.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">216.57</td>
<td align="right">-2.10</td>
<td align="right">-0.97</td>
<td>39.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">210.11</td>
<td align="right">-1.87</td>
<td align="right">-0.89</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">87.08</td>
<td align="right">-0.74</td>
<td align="right">-0.85</td>
<td>157.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.47</td>
<td align="right">-0.27</td>
<td align="right">-0.53</td>
<td>326.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">133.75</td>
<td align="right">-0.64</td>
<td align="right">-0.48</td>
<td>389</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">149.40</td>
<td align="right">-0.18</td>
<td align="right">-0.13</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.90</td>
<td align="right">-0.08</td>
<td align="right">-0.10</td>
<td>465</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">79.30</td>
<td align="right">-0.03</td>
<td align="right">-0.04</td>
<td>5.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For March 4, 2025

Mizuho analyst Gregg Moskowitz upgrades Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) from Neutral to Outperform and raises the price target from $110 to $127.

Upgrades

Price Target

Analyst Ratings

OKTA

Mizuho Upgrades Okta to Outperform, Raises Price Target to $127

OLPX

Olaplex Holdings shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY25 sales guidance above estimates.

Earnings Beats

QXO Q4 2024 GAAP EPS $(0.02), Sales $14.743M Beat $14.000M Estimate

Eric Trump's recent comments on the <a href="https://www.benzinga.com/25/03/44087250/strategys-saylor-calls-crypto-reserve-bullish-for-bitcoin-predicts-100-trillion-opportunity">strategic crypto reserve announcement</a> have sparked mixed reactions, with some praising him while others criticize the Trump family&#8217;s involvement in the industry.
What Happened: In an <a href="https://x.com/EricTrump/status/1896552942838350001">X</a> post on Monday, Eric Trump expressed gratitude after popular crypto trader AltcoinGordon credited his late-February &#8220;buy the dips&#8221; advice when Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) dropped below $90,000 on Feb. 25. 
Gordon tweeted, "Never fade Eric Trump," to which Trump responded by saying he's happy he could help and recommends investors to hold for the long term.
His post triggered a variety of reactions from the crypto community.
Michael Saylor echoed the sentiment, simply posting "HODL," while industry expert Quinten Francois warned to not bet against the Trump family.
Influencer Ted Pillows questioned if Trump was suggesting holding even through losses and jokingly proposed a Friday announcement to trigger a 500% rally.        
Economist Peter Schiff <a href="https://x.com/PeterSchiff/status/1896637889687204155">slammed</a> Trump's so-called &#8220;genius&#8221; Sunday announcement, arguing there was no formal agreement on a strategic reserve. 
He called it a pump and dump, suggesting the timing was intentional to maximize impact when trading volume was thin.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44080002/crypto-czar-david-sacks-confirms-selling-all-bitcoin-ethereum-solana-holdings-denies-large-indirect-holdings">Crypto Czar David Sacks Confirms Selling All Bitcoin, Ethereum, Solana Holdings, Denies &#8216;Large Indirect Holdings&#8217;</a>
What's Next: In another <a href="https://x.com/PeterSchiff/status/1896687148516221227">X</a> post, Schiff specifically called out Ethereum's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) performance following Trump's so-called "Truth Social Sunday Ethereum pump." 
He pointed out that ETH ETFs are at record lows, down 40% from their launch about eight months ago and 49% below their December 2023 highs.
Schiff predicted that Ethereum still has significant downside ahead, warning investors of further declines.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44085332/peter-schiff-says-trump-forcing-us-taxpayers-to-buy-bitcoin-and-other-worthless-crypto-is-preventing-the-market-from-collapse">Peter Schiff Says Trump Forcing US Taxpayers To Buy Bitcoin &#8216;And Other Worthless Crypto&#8217; Is Preventing The Market From Collapse</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Eric Trump Said 'Buy The Dips' In February, But Peter Schiff Isn't Buying The 'Genius' Bitcoin, XRP, Cardano Strategic Reserve Announcement

PEPG

PepGen To Temporarily Pause CONNECT2-EDO51 Study And Focus Efforts On CONNECT1-EDO51 Study Of PGN-EDO51 In DMD

Biotech

General

ABBV

AbbVie Announces SKYRIZI Available In Canada For Treatment Of Ulcerative Colitis Following Health Canada Approval

WINT

Windtree shares are trading higher after the company announced the USPTO issued a Notice of Allowance for its patent titled "Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure."

Barclays analyst Adam Seiden maintains MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) with a Overweight and raises the price target from $130 to $145.

Barclays Maintains Overweight on MasTec, Raises Price Target to $145

Sensus Healthcare, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/SRTS#NASDAQ">SRTS</a>), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery.
The single-site, retrospective study evaluated the clinical outcomes of combining surgical excision of keloids with primary wound closure followed by adjuvant Superficial Radiation Therapy (SRT) using Sensus Healthcare's SRT-100&#xAE; system. The findings from follow-up visits involving 12 patients with 16 keloids indicate that no keloid recurrence was observed with most patients followed for more than six months, highlighting the efficacy of this treatment approach. This is Sensus Healthcare's first study in Asia and was conducted at Tri Service Military Hospital in Taiwan, which has been using the SRT-100&#xAE; since 2023.

SRTS

Sensus Healthcare Announces Publication Of Study At Tri Service Military Hospital In Taiwan Demonstrating Efficacy Of SRT-100 In Preventing Keloid Recurrence

Windtree Announces USPTO Issued Notice Of Allowance Of US Patent Titled 'ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE'

SENS

Senseonics Holdings shares are trading lower. The company reported Q4 financial results.

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) (BMV:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#BMV">ZENA</a>) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, today announces that its Taiwan subsidiary, Spider Vision Sensors, is in the process of expanding its East Asian partnerships to sell to customers in the rapidly growing government defense and commercial drone markets. The company is also expanding its partnerships with local component manufacturers to further US military compliance in manufacturing sensors, cameras and parts for its ZenaDrone 1000 and IQ series multifunction AI drones. ZenaTech has hired two business development managers with plans to add up to five engineers over the next month to join the Spider Vision Sensors office team.

Global

BMV:ZENA

ZENA

ZenaTech's Taiwan Subsidiary Developing Partnerships In East Asia To Sell To The Fast-Growing Defense And Commercial Drone Markets

Legal

LSPD

Lightspeed Commerce Announces United States District Court for the Eastern District of New York Dismisses In Full Securities Class Action Lawsuit Against Co.

Barclays analyst Ryan McKeveny maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Equal-Weight and lowers the price target from $70 to $58.

GTLB

Barclays Maintains Equal-Weight on GitLab, Lowers Price Target to $58

Highlights:
<ul>
<li>FICO remains a leader in innovation, with advancements in decision-making, machine learning, and AI-related technology.</li>
<li>FICO's current patent portfolio consists of 226 U.S. and foreign active patents, with additional 75 patent applications filed and pending.</li>
</ul>
Global analytics software leader FICO was awarded new patents by the U.S. Patent and Trademark Office, encompassing technologies in fraud, artificial intelligence, machine learning, decision management and cybersecurity. The new patents showcase FICO's continuous innovations and leadership in operationalizing AI to deliver tangible results.
To date, FICO's patent portfolio includes over 200 U.S. and international patents. These patents represent innovative technologies aimed at helping drive profitability, customer satisfaction, customer protection, and growth across industries such as financial services, telecommunications, healthcare, retail, transportation, supply chain, and more.
The technology covered by FICO's new patents include:
<ul>
<li>A Latent-Space Misalignment Measure of Responsible AI for Machine Learning Models – This method covers technological improvements that identify misaligned data in a latent space for machine learning models. The innovation provides valuable new techniques to measure the degree of misalignment of a given data source with respect to an underlying machine learning model, both during development and production, and thereby furthers a core tenant of Responsible AI.</li>
<li>Enhanced Data Privacy Through Structure-preserving Autoencoders with Latent Space Augmentation – This is a method for generating refined (de-identified and anonymized) synthetic data from one or more sources of data.</li>
<li>Method and Apparatus for Analyzing Coverage, Bias, and Model Explanations in Large Dimensional Modeling Data - This method improves the fairness and transparency of AI models by identifying biases and weaknesses in large, complex datasets. By analyzing how AI models make decisions and the data on which they are built, it helps ensure the models are more accurate and explainable, which is crucial for building trust and accountability in AI systems.</li>
<li>Latent Feature Dimensionality Bounds for Robust Machine Learning on High Dimensional Datasets - This technology optimizes architectures of neural network models by compactly processing complex data, enhancing their stability and reliability. It helps ensure better performance when handling large, high-dimensional datasets, making machine learning models more accurate and dependable.</li>
<li>Data Distillery for Signal Detection - This system identifies important patterns or "signals" within vast datasets, helping businesses prioritize key insights to utilize in models and risk strategies. It streamlines data analysis of relevant business signals making decision management more efficient and effective.</li>
<li>Facial Recognition for User Authentication - This technology enhances user authentication by leveraging facial recognition to securely verify identities. Its integration with transaction fraud detection can strengthen the identification of potentially compromised accounts.</li>
<li>System and Method for Linearizing Messages from Data Sources for Optimized High-Performance Processing in a Stream Processing System - This technology is useful for handling large streams of real-time data, such as in financial or customer service systems.</li>
<li>Interpretable Feature Discovery with Grammar-based Bayesian Optimization - This method uses Bayesian search to discover and optimize key features in data, making machine learning models more understandable and interpretable. It helps ensure AI decisions are transparent, making it easier to trust the outcomes generated by these systems.</li>
<li>Managing Missing Values In Datasets For Machine Learning Models - This technology addresses missing data elements and handling in machine learning models by filling in gaps. It provides strategies for AI systems to remain reliable when data elements are incomplete.</li>
<li>Attributing Reasons to Predictive Model Scores - This improvement helps explain the factors that influence predictive model scores, making it easier to understand how decisions are made and providing rationale to consumers. It's particularly valuable in fraud detection systems like FICO&#xAE; Falcon&#xAE; Fraud Manager and any transaction analytic AI, ensuring transparency in transaction patterns driving outcomes and trust in scoring.</li>
<li>Cyber Security Adaptive Analytics Threat Monitoring System and Method - This system detects malware and other security threats by analyzing DNS and other network communication messages to assess threats. It provides businesses with real-time insights into potential attacks on key information and financial systems, helping them protect against cyber-attacks and data being actively infiltrated.</li>
</ul>

FICO

FICO Announces 12 New Patents, Advancing Responsible AI, Machine Learning, And Applied Intelligence Technology

<ul>
<li>Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3&#x2122; LVAD patients</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cadrenal.com%2F&amp;esheet=54218519&amp;newsitemid=20250304792377&amp;lan=en-US&amp;anchor=Cadrenal+Therapeutics&amp;index=1&amp;md5=849cf8be59121165ab208f7f5b1ad1c8">Cadrenal Therapeutics</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapeutics, with the late-stage asset tecarfarin, a new oral Vitamin K antagonist (VKA), today announced the signing of a Collaboration Agreement with Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) to support Cadrenal's pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
Under the terms of the Collaboration and Data Sharing Agreement, Abbott will support Cadrenal on the planning and execution of the TECH-LVAD trial to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the Agreement, Abbott will share insights from recent HeartMate 3&#x2122; trials and will support Cadrenal with: trial design, site identification, trial awareness, and HeartMate 3&#x2122; expertise.

CVKD

Cadrenal Therapeutics Announces Collaboration Agreement With Abbott In Support Of Pivotal Study Of Tecarfarin In Patients With HeartMate 3 LVAD

Contracts

Xactus Announces It Has Collaborated Up With Xactus As Its First Technology Partner To Bring Its FICO Score Mortgage Simulator To Market.

Press Releases

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Management

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Comments

Viracta Therapeutics

Viracta Therapeutics (VIRX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL